---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-000444"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:15:16.406643+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics enters license/supply deal with Celltrion for oral ustekinumab biosimilar

## Summary
- Rani obtains exclusive worldwide royalty-free license to Celltrion's ustekinumab biosimilar for oral delivery using Rani's platform.
- Celltrion will supply the biosimilar; Rani must purchase exclusively from Celltrion unless supply disruption.
- Celltrion has right of first negotiation for commercialization after Phase 1 data package; 30-day exercise, 90-day negotiation.
- Rani owns all data from research and development; can terminate for convenience; Celltrion can terminate if milestones not met.

## SEC filing metadata
- accession: 0000950170-23-000444
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000095017023000444/0000950170-23-000444-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000095017023000444/rani-20230106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-000444
- JSON: https://secwatch.observer/filing/0000950170-23-000444.json
- Plain text: https://secwatch.observer/filing/0000950170-23-000444.txt

## Key facts
- Material Agreements
  Rani Therapeutics Holdings, Inc. entered into License Agreement with Celltrion, Inc. (effective 2023-01-06).
  - Action: entry
  - Agreement: license
  - Counterparty: Celltrion, Inc.
  - Effective: 2023-01-06
  source text: On January 6, 2023, Rani Therapeutics, LLC, an operating subsidiary of Rani Therapeutics Holdings, Inc. (“Rani”), and Celltrion, Inc. (“Celltrion”) entered into a License and Supply Agreement (the “License Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1856725/000095017023000444/0000950170-23-000444-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.